William Blair analyst Andrew Brackmann has maintained their bullish stance on GH stock, giving a Buy rating yesterday.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Andrew Brackmann has given his Buy rating due to a combination of factors that emphasize Guardant Health’s favorable medium- and long-term prospects, even as investors concentrate on near-term catalysts. He highlights the upcoming ODAC review of AstraZeneca’s camizestrant, noting that a positive outcome could further endorse Guardant’s circulating tumor DNA–based “monitor-to-treat” approach, strengthening the company’s strategic position in oncology diagnostics.
At the same time, he points to the forthcoming earnings call, where the market is expecting modest revenue outperformance and solid Shield test volumes, as an opportunity to showcase accelerating growth and improving profitability. Brackmann views any short-lived share price pressure around these events as limited and potentially attractive entry points, reinforcing his conviction that Guardant Health should continue to outperform over the next several years.
Brackmann covers the Healthcare sector, focusing on stocks such as QuidelOrtho, Guardant Health, and Hologic. According to TipRanks, Brackmann has an average return of 15.1% and a 49.43% success rate on recommended stocks.
In another report released yesterday, Piper Sandler also maintained a Buy rating on the stock with a $130.00 price target.